Icon posts Q3 gains but more early phase capacity cuts planned in UK

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Revenue, Remainder, Uk

Icon posts Q3 gains but early phase cuts planned
Icon posts Q3 gains but early phase cuts planned
Despite a strong Q3, Icon has outlined plans for further cuts at its UK clinical pharmacology unit (CPU) as it rejigs its ‘weak’ early phase services business.

The Ireland-based contract research organisation (CRO) unveiled the plan during its Q3 earnings call last week with CEO Ciaran Murray setting it in context of a wider early phase reorganisation that saw the firm consolidate US capacity into a single site in San Antonio.

We continue to review our global capacity in the CPU in light of market conditions” ​adding - according to a transcript of the call​ - that “in the fourth quarter, we expect to move [to] further reduce capacity in our UK CPU as we focus on our new translational services business, which was based in Manchester​.”

He explained that Icon’s early phase services business was weak in the three months to September 30 – continuing the trend seen in the second quarter​ - and predicted that it “will be weak for the remainder of 2013.”

Growth in Q3

Early phase weakness and impending UK cuts aside, Icon had a quarter of growth with net revenue of $340m (€246m), up 19% on the equivalent period in 2012. Operating Income reached $33.2m, or 9.8% or revenue, compared with $20.9m or 7.3% of revenue last year.

Murray attributed the gains to an increase in bookings and lower cancellations, telling analysts that: “Gross bookings for the quarter were $471m, cancellations were $56m. This gives us net bookings for the quarter of $415m, which is a book-to-bill of 1.22.

Our backlog now stands at $2.97bn, which is 11% higher than this time last year and the backlog is currently given a 77% forward coverage the next 12 months revenue expectations​.”

The firm also raised its full year guidance for the third time and now expects to end the year with revenue of between $1.3bn and $1.33bn and earning per share of 1.67 - $1.70.

Strategic growth

Analyst Ross Muken from ISI said Icon’s Q3 and revised guidance “make us increasingly confident in ICLR’s ability to execute on its strategy and create shareholder value” adding that catalysts include “momentum on strategic deals, which could drive backlog upside.”

He did inject a note of caution, suggesting that the spending needed to support work from larger strategic clients could impact earning in the near term.

Generally Muken was positive about Icon’s prospects, telling investors that: “Progress in the central lab remains crucial to ICLR’s medium-term goal of achieving double digit operating margins. Finally, we see incremental tuck-in M&A activity as a potential positive​ catalyst.”

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Related suppliers

Follow us


View more